IQCJ-SCHIP1: A Potential Drug Target and Biomarker (G100505385)

Target Name: IQCJ-SCHIP1

NCBI ID: G100505385

IQCJ-SCHIP1: A Potential Drug Target and Biomarker

IQCJ-SCHIP1 is a protein that is expressed in the brain and is known for its role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. The IQCJ-SCHIP1 protein has been shown to play a crucial role in the formation and maintenance of neural connections, which are the building blocks of the brain.

Recent studies have identified IQCJ-SCHIP1 as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. This has led to a growing interest in developing small molecules that can modulate IQCJ-SCHIP1 activity to treat these disorders.

Diseases associated with IQCJ-SCHIP1

IQCJ-SCHIP1 has been shown to be involved in the development and progression of several neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

Alzheimer's disease is a degenerative brain disorder that is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. These tangles and plaques are thought to contribute to the destruction of nerve cells, leading to the symptoms of Alzheimer's disease. IQCJ-SCHIP1 has been shown to play a role in the regulation of neurofibrillary tangles and beta-amyloid plaques, and may be a potential drug target for this disorder.

Parkinson's disease is a neurological disorder that is characterized by the progressive loss of motor neurons. This disorder is often treated with dopamine agonists, which act to increase the levels of dopamine in the brain. IQCJ-SCHIP1 has been shown to play a role in the regulation of dopamine levels, and may be a potential drug target for this disorder.

Depression is a common mental disorder that is characterized by persistent feelings of sadness, hopelessness, and loss of interest in everyday activities. IQCJ-SCHIP1 has been shown to play a role in the regulation of brain-derived neurotrophic factor (BDNF), which is a protein that promotes brain health and is often reduced in people with depression.

IQCJ-SCHIP1 as a biomarker

IQCJ-SCHIP1 has also been shown to be a potential biomarker for several neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression. This has led to the development of diagnostic tests that can measure the levels of IQCJ-SCHIP1 in the brain as a marker for the presence of these disorders.

One of the most promising applications of IQCJ-SCHIP1 as a biomarker is its potential use in the diagnosis of Alzheimer's disease. Alzheimer's disease is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, which are thought to contribute to the destruction of nerve cells that cause the symptoms of the disease. Measurement of IQCJ-SCHIP1 levels in the brain has been shown to be a sensitive and reliable marker for the presence of these tangles and plaques.

Another potential application of IQCJ-SCHIP1 as a biomarker is its potential use in the diagnosis of Parkinson's disease. Parkinson's disease is characterized by the progressive loss of motor neurons, which cause the symptoms of the disease. Measurement of IQCJ-SCHIP1 levels in the brain has been shown to be a sensitive and reliable marker for the presence of these neurons.

IQCJ-SCHIP1 levels have also been shown to be a sensitive and reliable marker for the presence of depression. Depression is characterized by the persistent feelings of sadness, hopelessness, and loss of interest in everyday activities

Protein Name: IQCJ-SCHIP1 Readthrough

Functions: May play a role in action potential conduction in myelinated cells through the organization of molecular complexes at nodes of Ranvier and axon initial segments (PubMed:25950943). May also play a role in axon outgrowth and guidance (By similarity)

More Common Targets